Using Tyrosine Kinase Inhibition in Neuroendocrine Tumors

Jason S. Starr, DO, discusses his approach to dose reduction of cabozantinib in patients with neuroendocrine tumors.

Jason S. Starr, DO, discusses the significance of the extrapancreatic neuroendocrine tumor cohort of the phase 3 CABINET trial of cabozantinib.

Lowell B. Anthony, MD, discusses the potential benefits of cabozantinib for patients for different types of patients with neuroendocrine tumors.

Jason S. Starr, DO, discusses the CABINET trial of cabozantinib in pancreatic neuroendocrine tumors.